DMD

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced positive results from Part A in a tiny group of 4 patients of the MOMENTUM Phase 2 study evaluating SRP-5051 in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. SRP-5051 is the company's...

Solid Biosciences Inc (NASDAQ: SLDB) shares are advancing strongly Wednesday following on an update on its clinical development program for its SGT-001, its gene transfer investigational candidate for Duchenne muscular dystrophy, or DMD. Biomarker Data Encouraging Solid Biosciences said biomarker...

Small-cap biotech Wave Life Sciences Ltd (NASDAQ: WVE) — which fell last week following a delay in the release of top-line data from its Huntington disease candidates — is once again under pressure Tuesday. What Happened Wave Life Sciences released final results Tuesday...

Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported some encouraging results from the first three patients treated with the company’s microdystrophin gene therapy program for Duchenne Muscular Dystrophy (DMD), sending the stock soaring higher by 40 percent Tuesday and prompting positive...

SUMMIT THERAPEU/S ADR (NASDAQ: SMMT) is conducting clinical trials for Duchenne muscular dystrophy, or DMD, and clostridium difficile infection, or CDI. The Analyst Janney analyst Yun Zhong initiated coverage of Summit Therapeutics with a Buy rating and $27 fair value estimate. The Thesis...

Just weeks into its life as a publicly traded company, Solid Biosciences Inc (NASDAQ: SLDB) caught the eyes of four analysts who assumed coverage Tuesday with a mix of Holds and Buys. Here is what one of the more bearish critics had to say. The Rating Goldman Sachs analyst Salveen Richter...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared by more than 10 percent Wednesday after the company reported encouraging results from a clinical trial of a therapy intended to treat Duchenne muscular dystrophy (DMD). Sarepta's drug called golodirsen showed that patients who suffer from...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a smid-cap biopharmaceutical company that focuses on the treatment of rare neuromuscular diseases including Duchenne muscular dystrophy, saw its stock peak north of $60 per share in late 2016 after the U.S. Food and Drug Administration green-lighted its DMD...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) dropped 2 percent Thursday on news of the FDA’s approval of Marathon Pharmaceuticals' Duchenne Muscular Dystrophy treatment. Emflaza previously secured priority review and orphan drug status, and the FDA green-lighted the product for...

Shares of Sarepta Therapeutics Inc (NASDAQ: SPRT) were under heavy selling pressure following a concerning report released by Leerink's Joseph Schwartz. Schwartz completed a MEDACorp payor survey and the results suggest the reimbursement landscape for Sarepta's therapy for the treatment...

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are up more than 23 percent on Tuesday after the company reported positive numbers on recently-approved Duchenne muscular dystrophy (DMD) drug Exondys 51 at the JPMorgan Healthcare Conference. The company reported that Exondys 51 saw sales of $5.4...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by more than 24 percent Tuesday. The catalyst for the move appears to be the company's 10:30 a.m. presentation at the JPMorgan Healthcare Conference, followed by an encouraging report by TheStreet's Adam Feuerstein. As...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared as high as $63.73 following a controversial decision by the U.S. Food and Drug Administration to approve the company's treatment of Duchenne muscular dystrophy in September 2016. Since the FDA's announcement, the stock has lost more than half...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a biopharmaceutical company that focuses on the treatment of rare diseases, such as Duchenne Muscular Dystrophy (DMD), has become one of the most debated stocks of 2016. After bottoming at $8 per share in early 2016 the stock soared as high as $63.73...

Sarepta Therapeutics Inc (NASDAQ: SRPT) has taken quite a disappointing round-trip for shareholders since the stock jumped from $27.99 to $63.73 in a matter of days back in September. On September 19, the FDA granted accelerated approval for Sarepta’s Exondys 51, which became the first...